Approved regulatory verdict
Evidence outlook
Approved: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Diffuse Large B-Cell Lymphoma · approved · Featured evidence · 4 Follicular Lymphoma · approved · Featured evidence · 4 approved Featured evidence · 4
Competitive landscape 2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Tafasitamab: this drug Approved Monoclonal antibody — Epcoritamab Approved Multispecific antibody — CTX112 Phase 1/2 Biologic (subtype unspecified) CD19
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (23 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4) October 2026 (1) Phase 1/2 Diffuse Large B-Cell Lymphoma Active not recruiting
Est. primary completion 2026-10-15 ·
NCT05455697 ·
CT.gov ↗ What to watch December 2026 (3) Phase 1 Lymphoma, B-Cell Active not recruiting
Est. primary completion 2026-12-31 ·
NCT04161248 ·
CT.gov ↗ What to watch Phase 1/2 CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma Recruiting
Est. primary completion 2026-12-31 ·
NCT05351593 ·
CT.gov ↗ What to watch Phase 2 Diffuse Large B-Cell Lymphoma Recruiting
Est. primary completion 2026-12-31 ·
NCT05890352 ·
CT.gov ↗ What to watch 2027 (10) January 2027 (3) Phase 2 Large B-cell Lymphoma Recruiting
Est. primary completion 2027-01 ·
NCT06760156 ·
CT.gov ↗ What to watch Phase 1 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2027-01-01 ·
NCT05943496 ·
CT.gov ↗ What to watch Phase 2 Diffuse Large B-Cell Lymphoma Active not recruiting
Est. primary completion 2027-01-16 ·
NCT04978584 ·
CT.gov ↗ What to watch February 2027 (1) Phase 2 Non-Hodgkin Lymphoma Recruiting
Est. primary completion 2027-02 ·
NCT05583071 ·
CT.gov ↗ What to watch April 2027 (1) Phase 1/2 Lymphoma, Non-Hodgkin Active not recruiting
Est. primary completion 2027-04-07 ·
NCT03930953 ·
CT.gov ↗ What to watch July 2027 (1) Phase 2 Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Active not recruiting
Est. primary completion 2027-07-27 ·
NCT05718869 ·
CT.gov ↗ What to watch August 2027 (1) Phase 2 Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Recruiting
Est. primary completion 2027-08-19 ·
NCT05615636 ·
CT.gov ↗ What to watch September 2027 (1) Phase 2 Marginal Zone Lymphoma Active not recruiting
Est. primary completion 2027-09-15 ·
NCT04646395 ·
CT.gov ↗ What to watch December 2027 (2) Phase 1 Follicular Lymphoma Recruiting
Est. primary completion 2027-12 ·
NCT07225439 ·
CT.gov ↗ What to watch Phase 2 Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Recruiting
Est. primary completion 2027-12-31 ·
NCT05786040 ·
CT.gov ↗ What to watch 2028 (3) May 2028 (1) Phase 1/2 Mantle Cell Lymphoma Recruiting
Est. primary completion 2028-05-01 ·
NCT06029309 ·
CT.gov ↗ What to watch September 2028 (1) Phase 3 DLBCL Recruiting
Est. primary completion 2028-09 ·
NCT06521255 ·
CT.gov ↗ What to watch December 2028 (1) Phase 1/2 Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis Recruiting
Est. primary completion 2028-12-31 ·
NCT06434363 ·
CT.gov ↗ What to watch 2029 (4) April 2029 (1) Phase 2 Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Not yet recruiting
Est. primary completion 2029-04-14 ·
NCT07582159 ·
CT.gov ↗ What to watch July 2029 (1) Phase 2 Follicular Lymphoma Recruiting
Est. primary completion 2029-07-08 ·
NCT06792825 ·
CT.gov ↗ What to watch December 2029 (2) Phase 2 Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Recruiting
Est. primary completion 2029-12-30 ·
NCT05910801 ·
CT.gov ↗ What to watch Phase 2 Follicular Lymphoma Not yet recruiting
Est. primary completion 2029-12-31 ·
NCT07585747 ·
CT.gov ↗ What to watch 2030 (2) January 2030 (1) Phase 2 Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell Not yet recruiting
Est. primary completion 2030-01-01 ·
NCT07502872 ·
CT.gov ↗ What to watch October 2030 (1) Phase 2 Follicular Lymphoma Not yet recruiting
Est. primary completion 2030-10-31 ·
NCT07731789 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (43) Diffuse Large B-Cell Lymphoma (15) Follicular Lymphoma (8) Other / comorbidity (23)
Phase 3 (4) Phase 2/3 (1) Phase 2 (23) Phase 1/2 (11) Phase 1 (4)